According to the National Institute of Health (NIH) management guidelines for COVID-19, no drug has yet to be proven as safe and effective for COVID-19 treatment. Remdesivir is currently under investigation and is not yet recommended by the NIH. [1], [2]
The two NIH-funded clinical trials, the Adaptive COVID-19 Treatment Trial (observing remdesivir alone) and the ACTT 2 trial (observing remdesivir plus baricitinib) are both used in hospitalized patients with evidence of lung involvement or need for oxygen supplementation. [2], [3], [4]